SR ONE CAPITAL MANAGEMENT, LP Long-Term Concentrated

CIK: 0001910264 · Show all filings

Period: Q2 2024 (← Previous) (Next →)

Filing Date: Aug 13, 2024

Total Value ($000): $319,402 (100.0% shares, 0.0% debt)

Holdings (9)

ACLX Arcellx, Inc. 40.5%

Value ($000) $129,511 Shares 2,346,630 Est. Cost $16.72 Unrealized +225.1%

CRSP CRISPR Therapeutics AG 17.7%

Value ($000) $56,654 Shares 1,048,951 Est. Cost $71.59 Unrealized -19.2%

SPRY ARS Pharmaceuticals, Inc. 10.7%

Value ($000) $34,150 Shares 4,012,903 Est. Cost $6.79 Unrealized +30.8%

ALMS Alumis Inc. 8.2%

Value ($000) $26,067 Shares 1,959,896 Est. Cost $13.30 Unrealized 0.0%

MLYS Mineralys Therapeutics Inc. 7.4%

Value ($000) $23,597 Shares 2,016,822 Est. Cost $16.34 Unrealized -22.9%

DSGN Design Therapeutics, Inc. 6.8%

Value ($000) $21,864 Shares 6,526,476 Est. Cost $16.67 Unrealized -76.6%

NKTX Nkarta, Inc. 6.2%

Value ($000) $19,700 Shares 3,333,333 Est. Cost $11.49 Unrealized -38.4%

ENGN enGene Holdings Inc. 1.5%

Value ($000) $4,715 Shares 500,000 Est. Cost $12.83 Unrealized 0.0%

KALA KALA Bio, Inc. 1.0%

Value ($000) $3,146 Shares 443,661 Est. Cost $6.61 Unrealized 0.0%

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
ACLX	Arcellx, Inc.	2,346,630	$129,511	40.5%	$16.72	+225.1%	Common Stock	03940C100
CRSP	CRISPR Therapeutics AG	1,048,951	$56,654	17.7%	$71.59	-19.2%	Common Shares	H17182108
SPRY	ARS Pharmaceuticals, Inc.	4,012,903	$34,150	10.7%	$6.79	+30.8%	Common Stock	82835W108
ALMS	Alumis Inc.	1,959,896	$26,067	8.2%	$13.30	0.0%	Common Stock	022307102
MLYS	Mineralys Therapeutics Inc.	2,016,822	$23,597	7.4%	$16.34	-22.9%	Common Stock	603170101
DSGN	Design Therapeutics, Inc.	6,526,476	$21,864	6.8%	$16.67	-76.6%	Common Stock	25056L103
NKTX	Nkarta, Inc.	3,333,333	$19,700	6.2%	$11.49	-38.4%	Common Stock	65487U108
ENGN	enGene Holdings Inc.	500,000	$4,715	1.5%	$12.83	0.0%	Common Shares	29286M105
KALA	KALA Bio, Inc.	443,661	$3,146	1.0%	$6.61	0.0%	Common Stock	483119202